Midatech Pharma plc logo
Midatech Pharma plc MTP

Annual report 2024
added 02-21-2026

report update icon

Midatech Pharma plc Net Debt 2011-2026 | MTP

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Midatech Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - -6.17 M -1.63 M -7.05 M -15.5 M -14.4 M -28.4 M -1.24 M - -

All numbers in GBP currency

Indicator range from annual reports

Maximum Minimum Average
-1.24 M -28.4 M -10.6 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
-47.4 M $ 2.19 -9.77 % $ 226 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Cabaletta Bio Cabaletta Bio
CABA
-188 M $ 3.34 0.45 % $ 3.9 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Codexis Codexis
CDXS
12.5 M $ 1.02 1.49 % $ 74.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.74 3.6 % $ 1.12 B canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Cerus Corporation Cerus Corporation
CERS
-6.33 M $ 2.6 1.37 % $ 480 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-206 M $ 3.87 -0.39 % $ 116 M franceFrance
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
-13.6 M $ 3.23 2.22 % $ 1.23 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
-226 M $ 41.75 0.19 % $ 1.32 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
-114 M $ 36.14 1.23 % $ 3.75 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
-189 M $ 13.98 1.27 % $ 5.7 B irlandaIrlanda
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
-706 M $ 23.77 2.99 % $ 2.91 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
263 K $ 8.41 -1.87 % $ 36.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
-16.6 M $ 1.94 0.01 % $ 130 M usaUSA
Curis Curis
CRIS
-17 M $ 1.1 -3.51 % $ 6.94 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
CorMedix CorMedix
CRMD
-43 M $ 7.16 0.42 % $ 364 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Champions Oncology Champions Oncology
CSBR
-8.23 M $ 6.14 3.89 % $ 83.9 M usaUSA
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
-2.99 M $ 0.72 -2.34 % $ 4.84 M usaUSA
Athira Pharma Athira Pharma
ATHA
-47.2 M - - $ 269 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-3.05 M - 17.91 % $ 11.1 M usaUSA
Altimmune Altimmune
ALT
-35.2 M $ 4.21 -2.32 % $ 299 M usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
3.45 M $ 3.88 -8.92 % $ 247 M usaUSA